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Abstract
Objectives
To assess and compare cortical thickness (CTh) of patients with prodromal Dementia with
Lewy bodies (pro-DLB), prodromal Alzheimer's disease (pro-AD), DLB dementia (DLB-d),
AD dementia (AD-d) and normal ageing.
Methods
Study participants(28 pro-DLB, 27 pro-AD, 31 DLB-d, 54 AD-d and 33 elderly controls) un-
derwent 3Tesla T1 3D MRI and detailed clinical and cognitive assessments. We used Free-
Surfer analysis package to measure CTh and investigate patterns of cortical thinning
across groups.
Results
Comparison of CTh between pro-DLB and pro-AD (p<0.05, FDR corrected) showed more
right anterior insula thinning in pro-DLB, and more bilateral parietal lobe and left parahippo-
campal gyri thinning in pro-AD. Comparison of prodromal patients to healthy elderly controls
showed the involvement of the same regions. In DLB-d (p<0.05, FDR corrected) cortical
thinning was found predominantly in the right temporo-parietal junction, and insula, cingu-
late, orbitofrontal and lateral occipital cortices. In AD-d(p<0.05, FDR corrected),the most
significant areas affected included the entorhinal cortices, parahippocampal gyri and
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parietal lobes. The comparison of AD-d and DLB-d demonstrated more CTh in AD-d in the
left entorhinal cortex (p<0.05, FDR corrected).
Conclusion
Cortical thickness is a sensitive measure for characterising patterns of grey matter atrophy
in early stages of DLB distinct from AD. Right anterior insula involvement may be a key re-
gion at the prodromal stage of DLB and needs further investigation.
Introduction
Dementia with Lewy bodies (DLB) is the second most common form of dementia after Alzhei-
mer's disease (AD), accounting for 15% to 20% of neuropathologically defined cases[1].Diag-
nostic classification of DLB is based on revised consensus criteria with core diagnostic features
of DLB being(1) recurrent visual hallucinations, (2) cognitive fluctuations, and (3) spontaneous
motor features of parkinsonism[1]. The presence of 2 or 3 of these core signs is sufficient for a
diagnosis of probable DLB[1].However, distinguishing DLB from AD continues to be difficult
because of overlapping clinical and neuropathological features between the two conditions.
The accurate differentiation of DLB and AD, however, is particularly important as:1) the aetio-
logical basis of both diseases is likely to be different[2];2) DLBs exhibit adverse sensitivity to
neuroleptics; and 3) DLBs have a differing prognosis compared to AD[3],but yet a better re-
sponse to cholinesterase inhibitors[4].
The diagnostic challenge becomes particularly salient in the early stages or prodromal stages
(pro-DLB) of disease when the disease is present but cognitive impairments are not sufficient
to lead to functional deficits in activities of daily living[5].In contrast to AD where there are sig-
nificant advances in the classification and definition of prodromal AD (pro-AD),[6]the diag-
nostic classification of pro-DLB remains in its infancy although a prodromal phase of DLB has
now been demarcated in DSM-V as mild neurocognitive disorder of Lewy body disease[7] and
preliminary descriptions of pro-DLB criteria have recently been described[8];broadly, pro-
DLB can be defined as those patients who meet the revised diagnostic criteria for DLB but in-
stead of dementia[1], fit the criteria for mild cognitive impairment (MCI)[5].
Pro-DLB has been described with a different cognitive pattern from pro-AD[9, 10]: at the
early stage of the disease, DLB patients have more visuospatial and letter fluency deficits than
AD, and AD patients more memory storage impairment than DLB[10, 11]; findings which are
in keeping with the cognitive profiles of AD and DLB patients when the dementia becomes
manifest[12]although the neuropsychological pattern of pro-DLB has been reported as more
heterogeneous than in pro-AD[11].
Nevertheless early identification of DLB, particularly in the prodromal phase (i.e. pro-DLB)
will be highly relevant to the development and testing of future disease modifying treatments
and thus there is urgent need to develop viable and sensitive biomarkers which can detect DLB
in its early stages. Furthermore determination of early biomarkers in DLB are necessary to help
guide the operationalization of future consensus criteria for pro-DLB[8].
Structural neuroimaging represents one potential biomarker area and, in particular, the
metric of cortical thickness (CTh), which is an advanced and relatively novel method of struc-
tural image analysis. This approach allows for the quantification and regional distribution of
cortical grey matter loss to be specifically examined which is in contrast to gyral or lobar volu-
metric studies which often combine grey matter and white matter within regional volumes.
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Previous cortical thickness studies in Dementia with Lewy Bodies at the stage of dementia
(DLB-d) compared to Alzheimer's disease at the stage of dementia (AD-d)have reported thin-
ning in the cingulate cortex, temporo-parieto-occipital areas, orbito-frontal cortex and insula
[13, 14]. However the precise pattern of atrophy in pro-DLB is not known although one might
hypothese posterior cortical changes might be a feature given: 1) Visuospatial dysfunction and
the manifestation of visual hallucinations may be early features of DLB [9, 10, 15]; 2) There is
tentative evidence from several studies using [18F]-fluoro-d-glucose (FDG) positron emission
tomography (PET)[16]that patients with prodromal DLB symptoms have occipital hypometa-
bolism[17].
Therefore the primary aim of this study was to investigate CTh patterns in subjects with
pro-DLB and we report MRI patterns of CTh in subjects with DLB at the stage of MCI (pro-
DLB) and established dementia (DLB-d), AD at the stage of MCI (pro-AD) and dementia
(AD-d),as well as data from healthy elderly controls (HC).We included comparator disease
groups to explore how cortical thinning may evolve from an early stage of disease (pro-DLB
and pro-AD) to later established disease (DLB-d and AD-d); similarly inclusion of pro-AD
group was also considered relevant as this would be the group from which pro-DLB would
most likely need to be most distinguished from in clinical practise.
We hypothesised that in pro-AD, the pattern of cortical thinning would involve predomi-
nantly the temporal lobe, and parietal association cortices. In contrast, we expected that the
pattern of cortical thinning in pro-DLB would be less diffuse involving predominantly
posterior structures.
Patients and Methods
Ethics
The research was approved by the local ethics committee from SXB named "Comité de Protec-
tion des PersonnesEst IV" and NCL named "NRES Committee North East Sunderland" and
"NRES Committee North East Newcastle & North Tyneside 2". All subjects or, where appropri-
ate, their nearest relative, provided written informed consent.
Subjects, assessments and diagnosis
One hundred and sixty eight individuals suspected of DLB or AD over the age of 50 were re-
cruited (see Fig 1: flow chart) from two European centres: 80were recruited from a community
dwelling population of patients referred to local Old Age Psychiatry, Geriatric Medicine or
Neurology Services from Newcastle upon Tyne (NCL); 88 were recruited from the tertiary
Memory clinic (CMRR) of Strasbourg (SXB) including Neurology and Geriatric Medicine Ser-
vices. Subjects underwent detailed clinical and neuropsychological evaluations. Common ele-
ments between centres included the assessment of motor parkinsonism with the Unified
Parkinson’s Disease Rating Scale Part III (UPDRS-III)[18], the Clinician Assessment of Fluctu-
ation (CAF)[19],the Mini-Mental State Examination (MMSE), the Clinical Dementia Rating
scale (CDR), the trail making task A(TMTA) and B (TMTB). For TMT A and B, normative
data from Tombaugh were used[20]. The neuropsychological evaluation of SXB included the
Free and Cued Selective Reminding Tests (FC-SRT)for verbal memory, DMS-48 for visual rec-
ognition memory, forward and back ward Digit span, WAIS code for attention and speed pro-
cessing, Frontal Assessment Battery (FAB) and phonemic fluencies for executive functions,
semantic fluencies, Oral denomination 80 items (DO80) for language, the Rey-Osterrieth
Complex Figure Test and Mahieux praxis evaluation. The neuropsychological evaluation of
NCL was a comprehensive neuropsychological battery: the Cambridge Cognitive Examination
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(CAMCOG) as well as F-A-S test and semantic fluencies. For the purposes of this paper we re-
port only those scales which were common to both centres (e.g. MMSE, TMTA and TMTB).
Pro-AD (n = 23),pro-DLB (n = 23), AD-d (n = 11), DLB-d (n = 3)(see Table 1)patients
from SXBunderwent Cerebrospinal fluid (CSF) analysis including measurement of tau, phos-
pho-tau, and amyloid-beta (1–42) (Innognetics’sInnotest, ELISA).Assessment of medial tem-
poral atrophy on brain MRI was performed using the standardised Scheltensscale (5 categories,
0–4) with 0 corresponding to no atrophy[21]. Anaetiologic diagnosis of the neurocognitive dis-
order for each patient was made using Dubois’ criteria for pro-AD (n = 27, 26 from SXB, 1
from NCL) and AD-d (n = 54, 16 from SXB, 38 from NCL)[6],and McKeith’s criteria (probable
DLB; two core symptoms) for DLB-d (n = 31, 3 from SXB, 28 from NCL)[1].Pro-DLB patients
(n = 28, 26 from SXB, 2 from NCL) were defined as patients with MCI (Petersen criteria)[22],
and a CDR of 0 or 0.5, and by McKeith's criteria (meeting probable DLB criteria except pres-
ence of dementia)[1] and this maps onto recent suggestions for potential pro-DLB criteria [8].
Similarly33 aged healthy and cognitively intact (no MCI) subjects were recruited from among
relatives and friends of subjects with neurocognitive disorders or volunteered via advertise-
ments in local community newsletters inNCL and SXB. Exclusion criteria for participation in
the study included contraindications for MRI, history of alcohol/substance misuse, evidence
suggesting alternative neurological or psychiatric explanations for their symptoms/cognitive
impairment, focal brain lesions on brain imaging or the presence of other severe or unstable
medical illness.All patients had formal assessment of their diagnosis bythree independent ex-
pert clinicians (JPT, AT, FB for NCL and FB, BC, NP for SXB) and controls underwent similar
Fig 1. Flow Chart of the present study on cortical thickness in prodromal and dementia stages of Lewy body dementia and Alzheimer's disease.
AD = Alzheimer’s disease; DLB = Dementia with Lewy bodies; MCI = Mild Cognitive Impairment. Prodromal DLB means patients with McKeith's criteria of
DLB with cognitive impairment but without dementia. Psychiatric pathologies included two patients with depression, one with bipolar disorder, and one
histrionic personality disorder; and one cognitive impairment due to severe sleep apnoea, one vitamin B12 encephalopathy, and one mitochondriopathy for
patients with MCI. Other brain pathologies included one Parkinson's disease dementia, one DLB with primary Sjögren's syndrome, one with chronic brain
autoimmune encephalitis and one dementia without evolution for more than 10 years, for patients with dementia
doi:10.1371/journal.pone.0127396.g001
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Table 1. Clinical and Demographic Features of Dementia with Lewy bodies patients, Alzheimer’s Disease Patients at the stage of MCI or prodromal
and dementia, and healthy elderly controls.
Pro-
DLBN = 28
DLB-d
N = 31
Pro-AD
N = 27
AD-d
N = 54
HC
N = 33
Test statistic,P Post hocg
Age, yearsa 67.5 (9.2) 77.7
(6.9)
69.3 (7.8) 75.7 (9.4) 72.4
(10.4)
F = 7.184,
P<.0001*
Pro-DLB<DLB-d and AD-
dPro-AD<DLB-d and AD-d
Educationb 1/2/3 11/4/8 5/10/2 11/3/12 10/26/7 1/14/11 H = 7.465, P =
.113
Gender (F/M) 16/12 10/21 7/20 22/32 18/15 χ2 = 8.860, P =
.065
Handedness (R/L) 26/2 26/5 24/3 50/4 29/4 χ2 = 3.264, P =
.515
MMSE scorea 27.6 (2.1) 20.5
(4.6)
26.9 (1.9) 20.8 (3.6) 29.4
(0.9)
H = 119.397,
P<.0001*
HC< AD-d, DLB-d and pro-
ADPro-DLB<AD-d and DLB-
dPro-AD<AD-d and DLB-d
TMTAcimpaired
subjects
60.7% 82.3% 32.0% 43.2% 0% H = 21.791,
P<.0001*
HC>DLB-d and pro-DLBPro-
AD>DLB-d
TMTBcimpaired
subjects
71.4% 88.2% 44.0% 72.0% 0% H = 27.536,
P<.0001*
HC>DLB-d, AD-d, pro-DLB
CDR sum of box 0/
0.5/1/2/3
2/26/0/0/0 0/0/22/8/
1
1/26/0/0/0 0/0/42/
12/0
33/0/0/
0/0
H = 157.167,
P<.0001*
HC< AD-d, DLB-d, pro-DLB
and pro-ADPro-DLB<AD-d
and DLB-dPro-AD<AD-d and
DLB-d
Parkinsonismc Rigidity0/1/2/3/4 7/20/1/0/0 8/8/8/5/2 23/4/0/0/0 49/5/0/0/
0
33/0/0/
0/0
H = 84.874,
P<.0001*
Pro-DLB>HC, pro-AD and
AD-dDLB-d>HC, pro-AD and
AD-d
Akinesia0/1/2/3/
4
10/14/3/1/0 3/13/12/
3/0
23/4/0/0/0 40/12/2/
0/0
31/2/0/
0/0
H = 73.814,
P<.0001*
Pro-DLB>HC, pro-AD and
AD-dDLB-d>HC, pro-AD and
AD-d
Tremor at
rest0/1/2/3/4
17/9/2/0/0 11/9/10/
1/0
27/0/0/0/0 52/2/0/0/
0
33/0/0/
0/0
H = 63.608,
P<.0001*
Pro-DLB>HC, pro-AD and
AD-dDLB-d>HC, pro-AD and
AD-d
Hallucinationsd 60.7% 90.3% 0% 1.8% 0% χ2 = 119.071,
P<.0001*
Fluctuationsd 92.9% 90.3% 0% 22.2% 0% χ2 = 102.417,
P<.0001*
CAFa 3.5 (3.6) 6.8 (4.9) 0.0 (0) 1.0 (2.7) 0 (0) H = 81.063,
P<.0001*
Pro-DLB>HC, pro-AD and
AD-dDLB-d>HC, pro-AD and
AD-d
RBDd 56.0% 56.6% 7.7% 3.7% 0% H = 65.852,
P<.0001*
Pro-DLB>HC, pro-AD and
AD-dDLB-d>HC, pro-AD and
AD-d
Treatmentd ChEI 28.6% 83.8% 48.1% 81.5% 0.0% χ2 = 72.997,
P<.0001*
Dopa 28.6% 35.5% 0.0% 0.0% 0.0% χ2 = 41.804,
P<.0001*
NL 10.7% 22.6% 0.0% 1.9% 0.0% χ2 = 20.177, P
= .0001*
CSFe Abeta-42 859.3
(336.7, 23)
796.3
(277.3,
3)
579.0
(287.4,
23)
525.8
(104.0,
11)
- F = 5.194, P =
.003*
Pro-DLB>AD-d and pro-AD
P-Tau 43.6 (13.9,
23)
66.0 (1.7,
3)
93.7
(36.8,23)
99.5
(39.5, 11)
- F = 14.111,
P<.0001*
Pro-DLB<AD-d and pro-AD
Tau 313.0
(286.3, 23)
430.7
(28.6, 3)
660.6
(355.4,
23)
679.0
(246.1,
11)
- F = 6.266, P =
.001*
Pro-DLB<AD-d and pro-AD
(Continued)
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clinical and cognitive assessments to patients to exclude any that may have had an occult MCI
or dementia.Patients with concomitant AD and DLB i.e.meetingbothMcKeith's(for probable
DLB) and Dubois’ criteria were also excluded (see Fig 1).
MRI data acquisition
Subjects from NCL and SXB underwent T1 weighted MR scanning on a 3T MRI systemwithin
2 months of the study assessment. NCLused an 8 channel head coil (InteraAchieva scanner,
Philips Medical Systems, Eindhoven, Netherlands) and SXB a 32 channel head coil (Verio-
syngo MR B17, Siemens magnetom). The sequence was a standard T1 weighted volumetric
sequence covering the whole brain (3D MPRAGE, sagittal acquisition, 1 mm isotropic resolu-
tion). 3D T1 of NCL had a matrix size of 240 (anterior-posterior) x 240 (superior-inferior) x
180 (right-left), a repetition time (TR) = 9.6ms, an echo time (TE) = 4.6ms, and a flip
angle = 8°. 3DT1 of SXB had matrix size of 192 (anterior-posterior) x 192 (superior-inferior) x
176 (right-left), a repetition time (TR) = 1900ms, an echo time (TE) = 2.53ms and a flip
angle = 9°. The acquired volume was angulated such that the axial slice orientation was stan-
dardised to align with the AC-PC line.
Imaging processing
Estimates of CTh were performed from cortical surface reconstructions computed from T1
weighted images using FreeSurfer (v. 5.1, http://surfer.nmr.mgh.harvard.edu/). The technical
aspects of these methods have been described,in detail, elsewhere[23, 24]. In brief, the process-
ing stream involved intensity non-uniformity correction, Talairach registration, removal of
non-brain tissue (skull stripping), white matter (WM) and subcortical grey matter (GM) seg-
mentation, tessellation of the GM-WM boundary then surface deformation following GM-CSF
intensity gradients to optimally place GM-WM and GM-CSF borders[23, 24]. Once cortical
models were generated, surface inflation, transformation to a spherical atlas and parcellation of
the cerebral cortex into regions based on gyraland sulcal structure were carried out[25]. This
technique used both intensity and continuity information from the entire 3D MR volume in
Table 1. (Continued)
Pro-
DLBN = 28
DLB-d
N = 31
Pro-AD
N = 27
AD-d
N = 54
HC
N = 33
Test statistic,P Post hocg
Hippocampi
atrophyf0/1/2/3/4
Left
hippocampus
14/10/2/2/0 5/12/9/4/
1
5/16/4/2/0 4/18/15/
15/2
27/5/1/
0/0
H = 61.935,
P<.0001*
HC<AD-d, DLB-d and pro-
ADPro-DLB<AD-d and DLB-
d
Right
Hippocampus
14/10/4/0/0 7/9/11/3/
1
5/14/7/1/0 4/16/19/
13/2
22/8/2/
1/0
H = 50.544,
P<.0001*
HC<AD-d, DLB-d and pro-
ADPro-DLB<AD-d and DLB-
d
a Mean (standard deviation).
bEducation: 1 = before High School, 2 = High School, 3 = University.
c As rated on Unified Parkinson's Disease Rating Scale15.
dPercentage.
e Mean (standard deviation, number of patients tested).
f according to Scheltens et al.,JNNP, 1992.
gTukey post-hoc test for ANOVA (F), Mann-Whitney post-hoc test on SPSS (H). CAF = Clinician Assessment of Fluctuation; CDR = Clinical Dementia
Rating; ChEI = CholinEsteraseInhbitor; Dopa = L-Dopa or dopaminergic agonists; MMSE = Mini-Mental Status Examination; NL = Neuroleptics (only
clozapin or quetiapin); N = number; RBD = Rapid Eye Movement sleep Behaviour Disorder; TMTA = Trail Making Test A; TMTB = Trail Making Test B;
UPDRS = Unified Parkinson's Disease Rating Scale.
doi:10.1371/journal.pone.0127396.t001
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the segmentation and deformation procedures to produce representations of CTh, calculated
as the closest distance from the GM-WM to GM-CSF boundaries at each vertex on the tessel-
lated surface[26].CTh measures were mapped to the inflated surface. All images were then
aligned to a common surface template and smoothed with a 20mm full width at half maximum
(FWHM) surface based Gaussian kernel.
Visual inspection of images at each step of the FreeSurfer processing stream were carefully
carried out (by FB and SJ.C) to ensure accurate Talairach transformations, skull strips, deep
GM and white/pial surface generation and tissue classifications. During this procedure,pial
and/or WM surface errors were initially identified in 47scans. Manual correctionswere then
performed on these scans such as removal of dura mater and/orthe applicationof a set of WM
control points as required, before regeneratingthe pialor WM surfaces or both.Modification to
the processing stream resulted in successful cortical surface regeneration of31 scans. However,
the remaining 16scans (1 healthy subject, 5AD-d, 1 pro-AD, 2 DLB-d and 7 pro-DLB), still ex-
hibited significant pial or WM surface errors and were therefore excluded. The dataset for sub-
sequent CTh analysis therefore comprised of 33 controls, 54 AD-d, 31 DLB-d, 27 pro-AD and
28 pro-DLB.
Statistical analysis
The Statistical Package for Social Sciences software (SPSS ver. 21.0.0.0, http://www-01.ibm.
com/software/analytics/spss/) was used for further statistical evaluation as required. Where ap-
propriate, differences in demographic and clinical data were assessed using parametric
(ANOVA, t-tests) and non-parametric tests (Kruskall-Wallis H, Mann-Whitney U). Post-
hocanalyses employedTukey and Mann-Whitney U for ANOVA and Kruskall-Wallis tests re-
spectively.For categorical measures, χ2 tests were applied. For each test statistic, a probability
value of<0.05 was regarded as significant.
Cortical thickness. Regional CTh between groups were examined on a vertex-wise basis
using the general linear model (GLM), performed with the QDEC software (http://surfer.nmr.
mgh.harvard.edu/fswiki/Qdec).
CTh was modelled as a function of group, controlling for effects of age and where applicable
‘MRI site sequence’ as nuisance covariates. CTh = 1Group1 + β2Group2 + β3 Age+ β4Sequence
+μ + ε (where μ is a constant and ε is error). Contrasts of interest were calculated using two-
tailed t-tests between the group estimates β1 and β2. Surface maps showing significant differ-
ences between groups were then generated. Effects of CTh on global cognition(MMSE) were
investigatedwith age and MRI site sequence as nuisance variables. CTh was modelled as a func-
tion of covariate of interestCTh = β1MMSE+β2Age + β3Sequence+μ+ ε. Contrasts of interest
were calculated from the estimate β1, and whether β1 was significantly different from zero. For
all statistical analyses, a false discovery rate approach (FDR) was used.
Results
Subject characteristics
The demographic data for patients and healthy subjects are summarised in Table 1. Subject
groups were well matched for education, gender and handedness. Patients with prodromal dis-
ease were younger than patients with dementia.Of the patients with pro-AD 9 presented with
amnestic MCI single domain and 18 with amnestic MCI multiple domain.Of the patients with
pro-DLB 2 presented with amnestic MCI multiple domain, 13 with non-amnestic MCI single
domain and 13 with non-amnestic MCI multiple domain. For pro-AD and pro-DLB, MMSE
scores were similar, and higher than in AD-d and DLB-d groups. For TMTA, patients with
DLB (pro-DLB or DLB-d) were more impaired than the healthy control group. DLB-d patients
Cortical Thickness in Prodromal DLB and Prodromal AD
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were also more impaired than pro-AD. For TMTB, patients with dementia (DLB-d and AD-d),
and pro-DLB were more impaired than healthy controls.As expected, CDR scores were higher
in the dementia groups than in the prodromal groups.Bothpro-DLB and DLB-d had signifi-
cantly higher motor parkinsonism (UPDRS III scores), higher CAF score, and higher preva-
lence rate of REM sleep behaviour disorder (RBD) than the other groups. Patients with DLB
(prodromal or dementia) were also on dopaminergic treatment and DLB-d patients had the
highest usage of neuroleptics (clozapine and quetiapine) compared to other groups.Across AD
and DLB, patients with dementia weremore often taking cholinesterase inhibitors than prodro-
mal patients.Patients with AD (prodromal and dementia) had a greater number ofabnormal
CSF biomarkers than DLB (prodromal and dementia). Visual rating of atrophy on MR scans
found overall patients with dementia had greater hippocampal atrophy than controls, whilst
DLB-pro had less atrophy than either AD or DLB-d.
Comparison of pro-DLB and healthy subjects
Areas of cortical thinning in pro-DLB compared to healthy subjects are shown in Fig 2 (first
column), (n = 61, df = 58, p<0.001, uncorrected) and Table 2(A). Two clusters were noted on
the right hemisphere: right insula/pars opercularis and in the right medial orbitofrontal re-
gions. No difference in cortical thinning was found post FDR correction (<0.05).
Comparison of pro-AD and healthy subjects
Areas of cortical thinning in pro-AD compared to healthy older individuals are shown in Fig 2
(third column, n = 63, df = 59, p<0.05, FDR corrected) and Table 2(B). In pro-AD, cortical
thinning was diffuse and involved temporal, parietal and frontal lobes. The most significant
areas affected were confined to the parietal lobes.
Comparison of DLB-d and healthy subjects
Regions of cortical thinning in DLB compared to healthy subjects are presented in Fig 2 (sec-
ond column, n = 64, df = 60, p<0.05, FDR corrected) and Table 2(C). In DLB-d, there was gen-
erally less cortical thinning than in AD-d when compared to healthy subjects. Significant areas
involved were the bilateral temporo-parietal junction, insula, cingulate and orbitofrontal corti-
ces, lateral occipital lobes and superior frontal and anterior cingulate.
Comparison of AD-d and healthy subjects
Cortical thinning in AD-d compared to healthy older subjects are represented in Fig 2 (fourth
column, n = 87, df = 83, p<0.05, FDR corrected) and Table 2(D). In AD-d, cortical thinning
was bilaterally diffuse and involved large areas of the temporal, parietal, frontal and occipital
lobes. The most significant areas affected included the entorhinal cortices, parahippocampal
gyri and parietal lobes.
Comparison of pro-AD and pro-DLB
Regions of cortical thinning comparing pro-AD and pro-DLB are displayed in Fig 3 (first col-
umn, n = 55, df = 51, p<0.05, FDR corrected) and Table 2(E). In pro-DLB, there was generally
less cortical thinning than in pro-AD. The most significant areas of thinning for pro-AD rela-
tive to pro-DLB were located in parietal lobes and left parahippocampal gyri, while for pro-
DLB compared to pro-AD this was confined to the right insula and pars opercularis.
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Comparison of AD-d and DLB-d
Comparing AD and DLB, areas of significant cortical thinning (Fig 3 second column, n = 85,
df = 81, p<0.05, FDR corrected, Table 2F) were observed in AD-d compared to DLB-din the
left entorhinal cortex.
Cortical thickness and cognition
We did not find an association between CTh and MMSE performance in pro-DLB (n = 28,
df = 26, p>0.05 FDR corrected).However in DLB-d subjects there was a positive association be-
tween MMSE and CThin widespread right hemispheric cortical areas including the pars trian-
gularis, superior frontal, medial orbitofrontal, middle temporal, supramarginal, inferior
parietal regions as well as precuneus, pars opercularis and insula (n = 31, df = 27, p<0.05 FDR
corrected).In combined DLB (pro-DLB and DLB-d, Fig 4) there was a positive correlation
Fig 2. Cortical thinning patterns in pro-DLB, pro-AD, DLB-d and AD-d compared to healthy older controls (A = Anterior, P = Posterior, FDR = False
Discovery Rate).
doi:10.1371/journal.pone.0127396.g002
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Table 2. Location and peak vertex significance of cortical thinning in pro-DLB, DLB-d, pro-AD and AD-d compared to healthy subjects as well as
pro-DLB relative to pro-AD, and DLB-d compared to AD-d.
x y z NVtxs Area (mm2) -log10P
(a) Pro-DLB vs. healthy subjects *
Left rostral middle frontal -43 32 25 92 51 3.25*
Rightinsula/parsopercularis 36 10 13 492 154 4.66*
Right medial orbitofrontal 14 46 0 319 182 3.32*
Right superior temporal 47 -26 6 63 29 3.18*
(b) Pro-AD vs. healthy subjects
Left superior parietal -30 -52 51 35551 16920 5.02
Left superior frontal -17 25 53 7510 4370 4.08
Left supramarginal -47 -41 27 1933 904 3.66
Left parahippocampal -34 -38 -12 665 303 2.94
Left precentral -35 -18 36 814 307 2.86
Left inferior temporal -48 -42 -20 1234 780 2.81
Left caudal middle frontal -36 17 50 1609 982 2.58
Left lateral orbitofrontal -21 12 -19 238 112 2.46
Right superior parietal 28 -44 61 47740 22788 6.01
Right middle temporal -60 -50 3 678 363 2.68
Right posterior cingulate 12 -21 38 354 128 2.64
Right medial orbitofrontal 14 44 -1 395 211 2.15
Right pars opercularis 46 5 19 71 31 1.90
(c) DLB-d vs. healthy subjects
Left fusiform -39 -63 -17 60864 30466 7.17
Left medial orbitofrontal -9 15 -16 4185 2471 2.78
Left superior frontal -9 34 52 182 104 1.82
Left postcentral -39 -22 -22 141 53 1.81
Left rostral middle frontal -44 30 25 44 25 1.76
Right precuneus 7 -60 20 72400 34876 6.65
Right superior frontal 13 48 34 4013 2353 3.03
Right precentral 44 4 23 641 311 2.63
Right medial orbitofrontal 7 31 -17 180 137 1.86
(d) AD-d vs. healthy subjects
Left entorhinal -20 -17 -26 91291 47438 10.48
Left postcentral -40 -26 48 647 248 1.72
Right entorhinal 22 -8 -30 71015 35943 8.29
Right superior frontal 16 45 38 10167 6104 2.79
Right precentral 16 -20 71 1280 546 2.14
(e) pro-DLB vs. Pro-AD
Left superior parietal -28 -51 38 26483 12123 6.52
Left parahippocampal -21 -19 -25 363 134 3.20
Left supramarginal -58 -34 28 340 175 2.46
Left precentral -26 -13 55 223 102 2.41
Left lingual -12 -58 -3 318 157 2.27
Left lateral occipital -43 -67 -3 264 150 2.26
Left fusiform -39 -72 -17 386 272 2.24
Right inferior parietal 33 -57 42 22042 10237 7.81
Right insula 36 9 13 1049 333 -5.66
Right precentral 26 -13 50 1428 607 3.71
(Continued)
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found in the bilateral temporal, parietal and insula, left cingulate, right isthmus and posterior
cingulate, bilateral rostral middle frontal and superior frontalgyri, left medial orbitofrontal and
right lateral orbitofrontal(n = 59, df = 55, p<0.05 FDR corrected).No association was observed
in pro-AD (n = 27, df = 23, p>0.05 FDR corrected).In AD-d subjects there was a positive rela-
tionship with MMSE and CTh in the cingulate cortex (rostral anterior, posterior, isthmus)and
superior frontal regions of the left hemisphere (n = 54, df = 50, p<0.05 FDR corrected). For
combined AD (pro-AD and AD-d, Fig 4), a positive association was also identified in the left
temporal lobe, cingulate (isthmus, posterior, rostral anterior), precuneus, fusiform, supramar-
ginal, precentral and rostral middle frontal (n = 81, df = 77, p<0.05 FDR corrected).
Discussion
We report distinct, yet differing patterns of cortical thinning in pro-DLB, DLB-d, pro-AD and
AD-d when compared to a group of healthy subjects. Pro-DLB was characterised by discrete
cortical thinning in the right anterior insula and adjacent pars opercularis. Pro-AD was charac-
terised by widespread cortical thinning in parietal lobe, and aspects of frontal and temporal
lobes. The CTh comparison of the pro-DLB and pro-AD showed more cortical thinning in
pro-AD in the parietal lobes and the parahippocampal regions. Only one region was thinner in
pro-DLB than in pro-AD patients: the right anterior part of insula and the adjacent pars
opercularis.
Cortical thinning was evident in the temporoparietal junction, parts of the temporal lobes
including parahippocampal regions, bilateral insula, cingulate cortices, lateral part of the occip-
ital lobes, and superior frontal and orbitofrontal cortices in DLB-d when compared to healthy
controls. These findings were consistent with previous reports using cortical thickness and
Voxel-Based Morphometry(VBM)[14, 27].In pro-DLB compared to healthy controls, there
was evidence of cortical thinning in right frontal and insula regions, although this was only evi-
dent in uncorrected comparisons suggesting that cortical thinning, certainly in the prodromal
stage of DLB is relatively mild.
AD-d was characterised by cortical thinning in confluent areas of parietal and temporal
lobes, and a significant part of frontal and occipital lobes. The CTh comparison of the DLB-d
and AD-d showed more cortical thinning in AD-d patients in left entorhinal cortex and this
observation is in line with cortical thinning patterns reported in other independent DLB-d and
AD-d datasets from the NCL group[14]. Furthermore this also aligns with other studies which
have noted that DLB-d patients when compared to AD-d patients tend to haveless atrophy in
the medial temporal regions particularly on the left[27], and the anterior part[28], but not in
the posterior cortex[29].Howevercomparisons involving AD-d were unbalanceddue to the
larger sample size, and therefore may incur increased type I errors and assuch,these results
should be interpreted more tentatively.
Table 2. (Continued)
x y z NVtxs Area (mm2) -log10P
Right precuneus 9 -59 45 270 103 2.46
(f) DLB-d vs. AD-d
Left entorhinal -20 -12 -28 221 89 4.88
Table depicts anatomical region, FreeSurferTalairach coordinates, number of vertices within each cluster (NVtxs), surface area (Area) (mm2) and peak
significance expressed as a—log10P value (e.g.,-log10P = 3 corresponds to p = 0.001. . .etc). All results are significant (p<0.05 FDR corrected) except
where noted by asterisk (*) which were uncorrected.
doi:10.1371/journal.pone.0127396.t002
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Fig 3. Patterns of Cortical thinning between Pro-AD and Pro-DLB and between AD-d and DLB-d (A = Anterior, P = Posterior, FDR = False Discovery
Rate).
doi:10.1371/journal.pone.0127396.g003
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In pro-AD cortical thinning was mainly seen in the parietal cortices; this is consistent with
previous findings using freesurferwhich have shown parietal involvement in the early phase of
AD but not the MTL; furthermore this pattern of atrophy has been demonstrated MCI patients
with an AD trajectory[30],although it is notable that VBM has been shown to find more MTL
atrophy than parietal with the same patients[31]. However from aCTh perspective, analysis
with freesurfer can only partially assess the MTL and cannot be used assess hippocampal vol-
umes. Nevertheless we confirmed on visual atrophy grading greater MTL atrophy in our AD-d
cohort compared to DLB-d cohort in line with previously published data[14, 32].
Correlations between MMSE and CTh in DLB (pro-DLB and DLB-d), and in AD (pro-AD
and pro-DLB) showed key regions associated with cognitive decline. However, no correlation
was found with prodromal patients, pro-AD or pro-DLB; this is likely to be a function of less
atrophy in prodromal patients and limits on the range of MMSE scores in these groups and
lack of sensitivity of the MMSE to subtle cognitive deficits.
A key finding was the observationthat right anterior insula was thinner in pro-DLB and this
thinning became more manifest at the dementia stage. In comparison, in pro-AD insular thin-
ning was not evident;this is not unexpected as this region is not a part of the cortical thinning
signature in early AD[33]. However with disease progression in AD where there is markedcel-
lular loss, there is evidence of widespread cortical thinning which included insular areas (Fig
2). Thus insula thinning appears to be a feature of pro-DLB and not pro-AD but with time this
difference becomes less apparent once dementia manifests. The thinning of the anterior insula
was also associated with lower MMSE in the DLB-d and combined DLB-d and pro-DLB co-
hort. The insula isinvolved in integrating somatosensory, autonomic and cognitive-affective in-
formation to guide behaviour[34], and specifically the anterior insula has been described as
part of a ‘salience network’ due to its consistent activation during cognitively demanding tasks,
and the ability of this network to switch between brain networks involved in cognition, includ-
ing the central executive and default-mode network[35].Interestingly, the anterior insular has
certain specific neurons namely the Von Economo neurons (VENs), located in layer 5 of the
cortex with a predominance in the right hemisphere, the same region we have found thinner
in pro-DLB[36].Because of the larger size of VENs compared to pyramid neurons, they are
purported be involved in the fast assessment of complex situations[36] and the 'salience net-
work'[37] and thus it might been hypothesized that deficits in this region might be pertinent to
the cognitive slowing and attentional deficits which typify DLB. Certainly abnormal resting
state functional connectivity encompassing areas such as the right insula and right frontal
operculum has been previously observed in DLBpatients with cognitive fluctuations[38].Inter-
estingly, a recent voxelwisemeta-analysis on cortical atrophy of DLB patients at the stage of de-
mentia found a bilateral insula atrophy[39]. Moreover, we recently described a right anterior
insula atrophy of patients with cognitive neurodegenerative diseases and hallucinations[40].
Our study has somelimitations.Perhaps most salient is the fact thatwhilst there is an increas-
ing recognition that DLB has a prodromal state there is no consensus,as yet, regarding itsclini-
cal definition. In the absence of this we have utilised a combination of pre-existing criteria for
MCI and DLB criteria; however it is unknown whether these criteria are optimal for prodromal
DLB and we have no neuropathological confirmation of the diagnoses of any of our patients at
present. However, we have used McKeith's criteria which has excellent specificity (more than
95%) [41, 42] when compared to gold standard neuropathological diagnosis.In addition, we
also excluded other pathologies such as psychiatric illness, other neurological diseases, and also
Fig 4. Correlations between cortical thickness and MMSE for dementia with Lewy bodies (pro-DLB and DLB-d: DLB) and Alzheimer's disease (pro-
AD and AD-d: AD) patients (A = Anterior, P = Posterior, FDR = False Discovery Rate).
doi:10.1371/journal.pone.0127396.g004
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co-occurrence ofAD and DLB (see flow chart). Furthermore more than 50% of our DLB pa-
tients have RBD, which improves the specificity of the diagnosis[43].We also systematically
looked for discrete clinical symptoms such as anosmia/hyposmia, constipation, and other auto-
nomic features (data not shown)[44],as these have been previously demonstrated to improve
the diagnostic specificity of the prodromal DLB patients[44].Another limitation is the cross-
sectional nature of our study; longitudinal studies as in AD will be necessary for themapping
the disease trajectory for patients in prodromal stage of DLB and how cortical thinning pat-
terns evolve in DLB.
Another challenge in our study was the relatively modest number of patients studied and
they spanned a range of disease severities.From a technical perspective, it could also be argued
that a drawback of our study was the fact that data was collected from two sites with differing
imaging protocols. However we controlled where possible for this in our analyses thus mini-
mising this potential confound.Lastly, a possible future analysiswould be to examinethe reliabi-
lityof the prodromal results for validation purposesusingresampling/subsampling techniques
although this would require larger cohorts.
In conclusion, our data suggest that cortical thickness may be a sensitive measure for char-
acterising grey matter atrophy in early stages of DLB and its variance with patterns of grey
matter loss in early AD. In this context it may have a valuable role in delineating between pro-
dromal states of DLB and AD, as well as helping shapefuture diagnostic criteria for prodromal
DLB.
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